• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Inflammatory Breast Cancer International Consortium | IBC-IC HomepageInflammatory Breast Cancer International Consortium | IBC-IC

  • IBC Researchers + Centers
  • What is IBC?
  • About Us
  • Join IBC-IC
  • Research + Clinical Trials
  • Contact Us
  • Donate

< Back to Search Results

Beth Overmoyer, MD, FACP

Clinician + Researcher

Title(s)

  • Director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute
  • Institute Physician, Dana Farber Cancer Institute
  • Assistant Professor of Medicine, Harvard Medical School

Location(s)

  • Dana-Farber Cancer Institute
  • 450 Brookline Avenue
  • Boston, MA, 02215
  • United States of America
  • Phone: 617.632.6973
  • Fax: 617.632.1930

Research and Clinical Interests

IBC-Focused Research

Dr. Overmoyer launched the Inflammatory Breast Cancer (IBC) Program at the Dana-Farber Cancer Institute in 2009, where she continues to serve as its Director focusing on the development of IBC research programs and clinical trials.

She began her oncology career in 1989 at the University of Pennsylvania, where she trained in breast cancer and began her studies on inflammatory breast cancer. She went on to develop the breast cancer program at the Cleveland Clinic and later became the Director of Breast Cancer Research and the Director of the Clinical Trials Core at the Case Comprehensive Cancer Center in Cleveland.

She came to the Dana Farber Cancer Institute in 2007 and is an Institute Physician and Assistant Professor of Medicine at Harvard Medical School.


Clinical interests

  • Breast Cancer Clinical Trials
  • Breast Cancer Genetics
  • Inflammatory Breast Cancer
  • Systemic Treatment of Breast Cancer: Early Stage and Metastatic

IBC-Related News

  • Woman Suffering Inflammatory Breast Cancer Misdiagnosed
  • Exploring Breast Lumps and Cancer

Education and Board Certifications

MD

Case Western Reserve University School of Medicine, Cleveland, OH (1986)

Internship

Hospital of the University of Pennsylvania, Philadelphia, PA, Internal Medicine (1989)

Residency

Hospital of the University of Pennsylvania, Philadelphia, PA, Internal Medicine (1989)

Fellowship

Hospital of the University of Pennsylvania, Philadelphia, PA, Hematology/Oncology (1993)

Board Certification(s)

American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Medical Oncology
American Board of Internal Medicine - Internal Medicine

Years in Practice

31

Affiliations and Memberships

  • American Association for the Advancement of Science
  • American College of Physicians, Fellow
  • American Society of Clinical Oncology
  • Frontier Science Technology and Research Foundation IRB
  • National Consortium of Breast Centers
  • Translational Breast Cancer Research Consortium

Recent Publications

Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management
Annals of Surgical Oncology; August 2015

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Oncologist; January 2017

The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer
Annals of Surgical Oncology; May 2017

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Association of American Physicians and Surgeons; June 2017

Clinical Trials

NCI.gov – NCT02876302: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer

NCI.gov – NCT02623972: A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCI.gov – NCT01796197: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for inflammatory breast cancer

DF/HCC 12-156: Clinical and Pathological Correlation of Inflammatory Breast Cancer Imaging

View all clinical trials at clinicaltrials.gov >

Affiliated IBC-IC Center(s)

  • Dana-Farber Cancer Institute Inflammatory Breast Cancer Program
  • Boston, MA, 02215
  • Research + Treatment Center

Join IBC-IC

Become part of our international consortium of researchers, clinicians, advocates and centers worldwide dedicated to ending IBC.

Join >

IBCIC.org makes every effort to keep researcher information as up-to-date as possible.
Contact this researcher to confirm any information regarding his or her profile.

Footer

Inflammatory Breast Cancer International Consortium
420 E 70th St, LH 206
New York, NY 10021

Contact us

contact@ibcic.org